Global Factor VIII Market is segmented on the basis of type, disease management, application, and region. Hemophilia A, recessive X-linked coagulation disorder orAntihemophilic factor also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a blood clotting protein. It affects about 1 in 5000 males.
Factor VIII is a key factor of the intrinsic clotting cascade. Normal hemostasis requires at least a quarter of factor VIII activity. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene. Factor VIII is produced in liver sinusoidal cells and endothelial cells outside of the liver throughout the body circulating in the bloodstream in an inactive form in a stable noncovalent complex bound to von Willebrand factor (vWF).
Hemophilia A patients are treated with factor VIII concentrate for maintenance of normal hemostasis but unfortunately prophylactic treatment is not in general use around the world. Later on, recombinant factor VIII has been approved for therapeutic use, which lessens the risk of viral transmission. Factor VIII levels are of significance to measure not only to diagnose and monitor hemophilia but also for thrombophilia investigations. With the advent of chromogenic substrate technology, accurate and sensitive methods are available for quality control and for the clinical coagulation laboratory.
As per the US Centers for Disease Control and Prevention, hemophilia does occur in round about 1 in 5,000 live births. There are about 20,000 people with hemophilia in the U.S. Every race and ethnic group is affected. Hemophilia A is four times as common as hemophilia B while more as half of patients with hemophilia A have the stern form of hemophilia.
Concentrated FVIII from plasma or recombinant FVIII can be given to hemophiliacs to restore hemostasis. Factor VIII Market is classified, by type into Recombinant Factor VIII, Plasma-derived Factor VIII. Factor VIII Market is classified, by disease management into Prophylaxis, On-demand Therapy, and Inhibitor Therapy. Prophylaxis segment accounted for the largest market share of the Factor VIII Market in terms of revenue. The treatment involves the steady infusion of clotting factors in patients to maintain their levels higher at all times.
On-demand therapy segment is expected to grow at fastest pace over the forecast period. This treatment route is appropriate when bleeding needs to be arrested as soon as it begins and prevents its spread to joints and muscles. The slow acting on-demand hemophilia therapeutics for disease management finds important market opportunities in developing countries, where market penetration is increasing gradually.
Inhibitors are antibodies that are developed in hemophilia A patient with factor VIII, which is recognized as a foreign substance. Inhibitor therapies do involve a mixture of bypassing agent, high-dose clotting factor concentrate, and immune tolerance induction therapies. Developing economies are expected to register the highest growth rate in the years to come.
Factor VIII Market is classified, by application into Hemophilia A, Spontaneous/ Trauma, Surgical, and others. Factor VIII Market is segmented, geographically into North America, Europe (Eastern Europe, Western Europe), Asia Pacific, Latin America, Middle East and Africa. North America accounted for the largest market share of the Factor VIII Market in terms of revenue and is expected to remain dominant over the forecast period. This is mainly due to the high quality of the healthcare sector catering to the requirements of a large number of hemophilia patients in the region. Factor VIII Market key players are Baxter, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio and RAAS.
This report studies Factor VIII in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
• CSL Ltd. (Australia)
• Grifols S.A (Spain)
• Baxalta Incorporated (U.S.)
• Octapharma AG (Switzerland)
• Kedrion S.p.A (Italy)
• China Biologic Products, Inc. (China)
• Biotest AG (Germany)
• LFB S.A (France)
• Bio Product Laboratory Ltd. (U.K.)
• Sanquin (Netherlands)
Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Factor VIII in these regions, from 2011 to 2021 (forecast), like
• Southeast Asia
Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into
• Type I
• Type II
• Type III
Split by applications, this report focuses on sales, market share and growth rate of Factor VIII in each application, can be divided into
• Application 1
• Application 2
• Application 3
Research Support Specialist, USA